Combination therapy, which can optimize killing activity to cancers and minimize drug
resistance, is a mainstream therapy against hormone-refractory prostate cancers (HRPCs) …

Chemotherapy is a vital therapeutic strategy for castration-resistant prostate cancer (CRPC).
We have previously shown that NSC606985 (NSC), a camptothecin (CPT) analog, induced …

CFS-1686 (chemical name (E)-N-(2-(diethylamino) ethyl)-4-(2-(2-(5-nitrofuran-2-yl) vinyl)
quinolin-4-ylamino) benzamide) inhibits cell proliferation and triggers late apoptosis in …

Despite substantial breakthroughs in cancer research, there is hardly any specific therapy
available to date that can alleviate triple-negative breast cancer (TNBC). Paclitaxel is the first …

Rottlerin is a cytostatic and cytotoxic drug in a variety of cancer cells. Our previous
experience demonstrated that depending upon the genetic/biochemical background of …

Background Castration‐resistant prostate cancer (CRPC) is refractory to hormone treatment
and the therapeutic options are continuously advancing. This study aims to discover the anti …

Retigeric acid B (RB) has been reported to exhibit its anti-tumor activity in vitro and in vivo.
Here, we found that RB significantly inhibited activity of topoisomerase IIα (Topo IIα), leading …

Camptothecin (CPT) selectively traps topoisomerase 1-DNA cleavable complexes (Top1cc)
to promote anticancer activity. Here, we report the design and synthesis of a new class of …

Protein kinase C-δ (PKCδ) plays an important role in DNA damage–induced apoptosis. We
have previously shown that the PKCδ inhibitor rottlerin protects against cisplatin-induced …

Doxorubicin is among the most effective and widely used anticancer drugs in the clinic.
However, cardiotoxicity is one of the life-threatening side effects of doxorubicin-based …